Analysts forecast that Oncolytics Biotech, Inc. (NASDAQ:ONCY) will post earnings per share (EPS) of ($0.15) for the current quarter, Zacks reports. Zero analysts have made estimates for Oncolytics Biotech’s earnings. Oncolytics Biotech posted earnings per share of ($0.19) during the same quarter last year, which would indicate a positive year over year growth rate of 21.1%. The company is scheduled to announce its next quarterly earnings report after the market closes on Tuesday, August 4th.
On average, analysts expect that Oncolytics Biotech will report full-year earnings of ($0.40) per share for the current financial year, with EPS estimates ranging from ($0.45) to ($0.33). For the next financial year, analysts forecast that the business will report earnings of ($0.51) per share, with EPS estimates ranging from ($0.59) to ($0.39). Zacks Investment Research’s earnings per share calculations are an average based on a survey of research firms that follow Oncolytics Biotech.
Oncolytics Biotech (NASDAQ:ONCY) last issued its quarterly earnings data on Friday, May 8th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.01).
Several analysts have recently commented on the company. Roth Capital reissued a “buy” rating and issued a $9.00 price objective on shares of Oncolytics Biotech in a research note on Monday, May 11th. Canaccord Genuity reaffirmed a “buy” rating and set a $7.00 price target on shares of Oncolytics Biotech in a research report on Monday, June 1st. Royal Bank of Canada decreased their price target on Oncolytics Biotech from $9.00 to $6.00 and set an “outperform” rating for the company in a research report on Monday, May 11th. Zacks Investment Research downgraded Oncolytics Biotech from a “buy” rating to a “hold” rating in a research report on Tuesday, July 14th. Finally, Echelon Wealth Partners reaffirmed a “speculative buy” rating on shares of Oncolytics Biotech in a research report on Tuesday, June 16th. Three analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.88.
A number of hedge funds and other institutional investors have recently made changes to their positions in ONCY. Morgan Stanley grew its holdings in Oncolytics Biotech by 203.1% during the first quarter. Morgan Stanley now owns 425,212 shares of the company’s stock valued at $587,000 after purchasing an additional 284,934 shares during the period. Two Sigma Advisers LP bought a new position in Oncolytics Biotech during the first quarter valued at $208,000. Wedbush Securities Inc. grew its holdings in Oncolytics Biotech by 227.9% during the second quarter. Wedbush Securities Inc. now owns 146,605 shares of the company’s stock valued at $276,000 after purchasing an additional 101,900 shares during the period. Creative Planning bought a new position in Oncolytics Biotech during the first quarter valued at $128,000. Finally, Financial Consulate Inc. bought a new position in shares of Oncolytics Biotech in the second quarter worth $78,000. 1.42% of the stock is owned by institutional investors and hedge funds.
Shares of Oncolytics Biotech stock opened at $2.02 on Tuesday. Oncolytics Biotech has a 52 week low of $0.35 and a 52 week high of $6.02. The business has a 50 day moving average price of $1.96 and a 200-day moving average price of $2.09.
Oncolytics Biotech Company Profile
Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.
Featured Article: What is net income?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.